http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 21 May 2026 16:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++NovoCure+Ltd+++++++++++++++++++++++++/26535001.html si-local-file:///var/storage/secattach/20260521/26535001.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++NovoCure+Ltd+++++++++++++++++++++++++/26535001.html Thu, 21 May 2026 16:00:00 -0400 NVCR O.15717088 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++NovoCure+Ltd+++++++++++++++++++++++++/26535001.html si-local-file:///var/storage/secattach/20260521/26535001.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++NovoCure+Ltd+++++++++++++++++++++++++/26535001.html Thu, 21 May 2026 16:00:00 -0400 NVCR O.15717088 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NovoCure+Ltd+++++++++++++++++++++++++++Filed+by%3A+Soleus+Capital+Master+Fund%2C+L.P./26462284.html si-local-file:///var/storage/secattach/20260508/26462284.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NovoCure+Ltd+++++++++++++++++++++++++++Filed+by%3A+Soleus+Capital+Master+Fund%2C+L.P./26462284.html Fri, 08 May 2026 17:02:00 -0400 NVCR O.15717088 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NovoCure+Ltd+++++++++++++++++++++++++++Filed+by%3A+Soleus+Capital+Master+Fund%2C+L.P./26462284.html si-local-file:///var/storage/secattach/20260508/26462284.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NovoCure+Ltd+++++++++++++++++++++++++++Filed+by%3A+Soleus+Capital+Master+Fund%2C+L.P./26462284.html Fri, 08 May 2026 17:02:00 -0400 NVCR O.15717088 http://www.streetinsider.com/Analyst+PT+Change/NovoCure+Ltd.+%28NVCR%29+PT+Raised+to+%2417+at+Wells+Fargo/26420659.html Wells Fargo analyst Larry Biegelsen raised the price target on NovoCure Ltd. (NASDAQ: NVCR) to $17.00 (from $13.50) while maintaining a Equal Weight rating. http://www.streetinsider.com/Analyst+PT+Change/NovoCure+Ltd.+%28NVCR%29+PT+Raised+to+%2417+at+Wells+Fargo/26420659.html Mon, 04 May 2026 06:51:27 -0400 NVCR http://www.streetinsider.com/Analyst+PT+Change/NovoCure+Ltd.+%28NVCR%29+PT+Raised+to+%2420+at+Evercore+ISI/26404442.html <p>Evercore ISI analyst Vijay Kumar raised the price target on NovoCure Ltd. (NASDAQ: NVCR) to $20.00 (from $16.00) while maintaining a Outperform rating.</p> http://www.streetinsider.com/Analyst+PT+Change/NovoCure+Ltd.+%28NVCR%29+PT+Raised+to+%2420+at+Evercore+ISI/26404442.html Thu, 30 Apr 2026 12:22:01 -0400 NVCR http://www.streetinsider.com/Earnings/Novocure+%28NVCR%29+Misses+Q1+EPS+by+13c%2C+provides+guidance/26400506.html <p>Novocure (NASDAQ: NVCR) reported Q1 EPS of ($0.62), $0.13 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $174.1 million versus the consensus estimate of $167.77 million.</p><p><strong>GUIDANCE:</strong></p><p>Novocure sees FY2026 revenue of $690-710 million, versus the consensus of $694.7 million.</p><p>For earnings history and earnings-related data on Novocure (NVCR) <a href="http://www.streetinsider.com/ec_earnings.php?q=NVCR">click here</a>.</p> http://www.streetinsider.com/Earnings/Novocure+%28NVCR%29+Misses+Q1+EPS+by+13c%2C+provides+guidance/26400506.html Thu, 30 Apr 2026 07:13:19 -0400 NVCR http://www.streetinsider.com/Guidance/Novocure+%28NVCR%29+Misses+Q1+EPS+by+13c%2C+provides+guidance/26400506.html <p>Novocure (NASDAQ: NVCR) reported Q1 EPS of ($0.62), $0.13 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $174.1 million versus the consensus estimate of $167.77 million.</p><p><strong>GUIDANCE:</strong></p><p>Novocure sees FY2026 revenue of $690-710 million, versus the consensus of $694.7 million.</p><p>For earnings history and earnings-related data on Novocure (NVCR) <a href="http://www.streetinsider.com/ec_earnings.php?q=NVCR">click here</a>.</p> http://www.streetinsider.com/Guidance/Novocure+%28NVCR%29+Misses+Q1+EPS+by+13c%2C+provides+guidance/26400506.html Thu, 30 Apr 2026 07:13:19 -0400 NVCR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NovoCure+Ltd++++++++++++++For%3A+Apr+30/26400349.html si-local-file:///var/storage/secattach/20260430/26400349.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NovoCure+Ltd++++++++++++++For%3A+Apr+30/26400349.html Thu, 30 Apr 2026 07:02:00 -0400 NVCR O.15717088 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NovoCure+Ltd++++++++++++++For%3A+Apr+30/26400349.html si-local-file:///var/storage/secattach/20260430/26400349.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NovoCure+Ltd++++++++++++++For%3A+Apr+30/26400349.html Thu, 30 Apr 2026 07:02:00 -0400 NVCR O.15717088 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++NovoCure+Ltd++++++++++++++For%3A+Mar+31/26400298.html si-local-file:///var/storage/secattach/20260430/26400298.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++NovoCure+Ltd++++++++++++++For%3A+Mar+31/26400298.html Thu, 30 Apr 2026 07:01:00 -0400 NVCR O.15717088 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++NovoCure+Ltd++++++++++++++For%3A+Mar+31/26400298.html si-local-file:///var/storage/secattach/20260430/26400298.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++NovoCure+Ltd++++++++++++++For%3A+Mar+31/26400298.html Thu, 30 Apr 2026 07:01:00 -0400 NVCR O.15717088 http://www.streetinsider.com/Press+Releases/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html <p class="bwalignc"> Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® </p><p class="bwalignc"> Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). </p><p> “This http://www.streetinsider.com/Press+Releases/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html Thu, 30 Apr 2026 07:00:00 -0400 A.05963196 A.29816089 A.40151759 NVCR O.00036828 O.00050368 O.05375760 O.15717088 http://www.streetinsider.com/Press+Releases/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html <p class="bwalignc"> Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® </p><p class="bwalignc"> Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). </p><p> “This http://www.streetinsider.com/Press+Releases/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html Thu, 30 Apr 2026 07:00:00 -0400 A.05963196 A.29816089 A.40151759 NVCR O.00036828 O.00050368 O.05375760 O.15717088 http://www.streetinsider.com/Press+Releases/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html <p class="bwalignc"> Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® </p><p class="bwalignc"> Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). </p><p> “This http://www.streetinsider.com/Press+Releases/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html Thu, 30 Apr 2026 07:00:00 -0400 A.05963196 A.29816089 A.40151759 NVCR O.00036828 O.00050368 O.05375760 O.15717088 http://www.streetinsider.com/Press+Releases/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html <p class="bwalignc"> Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® </p><p class="bwalignc"> Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). </p><p> “This http://www.streetinsider.com/Press+Releases/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html Thu, 30 Apr 2026 07:00:00 -0400 A.05963196 A.29816089 A.40151759 NVCR O.00036828 O.00050368 O.05375760 O.15717088 http://www.streetinsider.com/Press+Releases/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html <p class="bwalignc"> Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® </p><p class="bwalignc"> Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). </p><p> “This http://www.streetinsider.com/Press+Releases/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html Thu, 30 Apr 2026 07:00:00 -0400 A.05963196 A.29816089 A.40151759 NVCR O.00036828 O.00050368 O.05375760 O.15717088 http://www.streetinsider.com/Press+Releases/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html <p class="bwalignc"> Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® </p><p class="bwalignc"> Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). </p><p> “This http://www.streetinsider.com/Press+Releases/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html Thu, 30 Apr 2026 07:00:00 -0400 A.05963196 A.29816089 A.40151759 NVCR O.00036828 O.00050368 O.05375760 O.15717088 http://www.streetinsider.com/Press+Releases/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html <p class="bwalignc"> Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® </p><p class="bwalignc"> Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). </p><p> “This http://www.streetinsider.com/Press+Releases/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html Thu, 30 Apr 2026 07:00:00 -0400 A.05963196 A.29816089 A.40151759 NVCR O.00036828 O.00050368 O.05375760 O.15717088 http://www.streetinsider.com/Press+Releases/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html <p class="bwalignc"> Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® </p><p class="bwalignc"> Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). </p><p> “This http://www.streetinsider.com/Press+Releases/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html Thu, 30 Apr 2026 07:00:00 -0400 A.05963196 A.29816089 A.40151759 NVCR O.00036828 O.00050368 O.05375760 O.15717088 http://www.streetinsider.com/Business+Wire/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html <p class="bwalignc"> Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® </p><p class="bwalignc"> Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). </p><p> “This http://www.streetinsider.com/Business+Wire/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html Thu, 30 Apr 2026 07:00:00 -0400 A.05963196 A.29816089 A.40151759 NVCR O.00036828 O.00050368 O.05375760 O.15717088 http://www.streetinsider.com/Business+Wire/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html <p class="bwalignc"> Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® </p><p class="bwalignc"> Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). </p><p> “This http://www.streetinsider.com/Business+Wire/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html Thu, 30 Apr 2026 07:00:00 -0400 A.05963196 A.29816089 A.40151759 NVCR O.00036828 O.00050368 O.05375760 O.15717088 http://www.streetinsider.com/Business+Wire/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html <p class="bwalignc"> Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® </p><p class="bwalignc"> Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). </p><p> “This http://www.streetinsider.com/Business+Wire/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html Thu, 30 Apr 2026 07:00:00 -0400 A.05963196 A.29816089 A.40151759 NVCR O.00036828 O.00050368 O.05375760 O.15717088 http://www.streetinsider.com/Business+Wire/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html <p class="bwalignc"> Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® </p><p class="bwalignc"> Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). </p><p> “This http://www.streetinsider.com/Business+Wire/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html Thu, 30 Apr 2026 07:00:00 -0400 A.05963196 A.29816089 A.40151759 NVCR O.00036828 O.00050368 O.05375760 O.15717088 http://www.streetinsider.com/Business+Wire/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html <p class="bwalignc"> Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® </p><p class="bwalignc"> Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). </p><p> “This http://www.streetinsider.com/Business+Wire/Novocure+Reports+First+Quarter+2026+Financial+Results/26400217.html Thu, 30 Apr 2026 07:00:00 -0400 A.05963196 A.29816089 A.40151759 NVCR O.00036828 O.00050368 O.05375760 O.15717088